Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals Inc (ADIL) is a clinical-stage biopharmaceutical company pioneering personalized treatments for alcohol use disorder through advanced pharmacogenomics. This page provides investors and healthcare professionals with essential updates on ADIL's clinical trials, regulatory milestones, and strategic initiatives.
Access timely announcements about the company's lead investigational drug AD04—a serotonin-3 receptor antagonist designed for genetically identified patient groups. Stay informed about clinical study results, FDA communications, intellectual property developments, and partnership opportunities that demonstrate ADIL's progress in addiction medicine.
Key updates include progress reports on the 505(b)(2) regulatory pathway, companion diagnostic advancements, and peer-reviewed research publications. All content is curated to help stakeholders track the company's evidence-based approach to treating addictive disorders through precision medicine.
Bookmark this page for direct access to primary source materials and analysis-free reporting on ADIL's scientific and corporate developments. Check regularly for new filings, trial data disclosures, and strategic announcements that shape the company's trajectory in biopharmaceutical innovation.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) addresses the growing problem of addiction exacerbated by the COVID-19 pandemic. CEO William Stilley and CMO Dr. Bankole Johnson highlighted the alarming rise in alcohol abuse, termed the 'Second Pandemic of Addiction,' with increased fatalities projected. Adial's Phase 3 drug candidate, AD04, aims to combat Alcohol Use Disorder, showing promising results in earlier trials. The ONWARD clinical trial involves 290 participants across seven countries and targets a genetically specific patient population.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced Dr. Bankole Johnson's interview on The Black News Channel, discussing the COVID-19 pandemic's long-term effects on mental health and addiction. The company focuses on developing treatments for addiction disorders, with its lead product, AD04, currently in a pivotal Phase 3 trial for Alcohol Use Disorder. Past results from a Phase 2b trial indicated a significant reduction in drinking frequency and quantity without major safety concerns. The replay of the interview is available on the company's website.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has entered into Securities Purchase Agreements for a private placement of 700,001 shares of common stock at $3.00 each, raising $2,100,000. The funding includes an initial $291,003, with $1,809,000 to be provided upon share registration. Investors include members of management and Keystone Capital Partners. Adial focuses on addiction treatment, with its lead drug AD04 currently in a pivotal Phase 3 clinical trial for Alcohol Use Disorder (AUD). The trial is being conducted across 25 sites in seven countries.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced a Town Hall meeting for shareholders on March 18, 2021, at 1 PM ET. The company focuses on developing addiction treatments, particularly its lead product, AD04, which is in a Phase 3 clinical trial for Alcohol Use Disorder (AUD). AD04 exhibited promising results in earlier trials. The ONWARD trial evaluates its efficacy in genetically selected patients across multiple locations in Europe. The company highlighted the necessity of ongoing clinical trials and regulatory approvals for its product candidates.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced the exercise of 712,500 warrants, generating net proceeds of $1,425,000. The funds will aid in advancing the development of AD04, a treatment for Alcohol Use Disorder (AUD), currently undergoing pivotal Phase 3 trials called ONWARD. This trial includes genetically targeted patients and is being conducted across seven countries. Previous Phase 2b trials of AD04 showed significant reductions in drinking frequency and quantity, with no major safety issues reported.
Adial Pharmaceuticals announced a significant milestone in its ONWARD™ pivotal Phase 3 clinical trial, achieving 50% enrollment for its lead drug candidate, AD04, targeting Alcohol Use Disorder. With 66% of planned patient screening visits completed, Adial expects to fully enroll by summer. 32% of screened patients are genetically positive for AD04, with a 75% enrollment rate among these patients. The trial retains an impressive 86% patient retention rate, surpassing the projected 70%. This trial, conducted across 25 clinical sites in Europe, investigates the drug's efficacy and safety.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced its intention to file for Fast Track designation with the FDA for its lead drug candidate, AD04, aimed at treating Alcohol Use Disorder (AUD). This follows an earlier request submitted in September 2020. Adial believes that AD04 qualifies due to the seriousness of AUD and the unmet medical need it addresses. The FDA typically reviews Fast Track applications within 60 days, assessing factors like treatment impact and safety compared to existing therapies. AD04 is currently undergoing a pivotal Phase 3 clinical trial.
Adial Pharmaceuticals will present an overview at the 23rd Annual ICR Conference on January 14, 2021, from 3:15 PM to 3:55 PM ET. CEO William Stilley will lead the presentation, which will focus on the company's advancements in treatments for addictions, particularly the investigational drug AD04 aimed at treating Alcohol Use Disorder (AUD). This drug is currently in a pivotal Phase 3 trial. A live webcast will be available on Adial's website, with replays accessible for 90 days.
Adial Pharmaceuticals (NASDAQ:ADIL; ADILW) announced the receipt of a Notice of Allowance for its third U.S. patent for AD04, aimed at treating Opioid Use Disorder (OUD) in patients with a specific genetic biomarker. CEO William Stilley highlighted the significant market potential for AD04, emphasizing its similar physiological effects in treating alcohol and opioid addictions. The CDC noted that approximately 2 million people in the U.S. had OUD in 2018, a number expected to have increased during the pandemic. AD04 is currently undergoing a pivotal Phase 3 trial for Alcohol Use Disorder.
Adial Pharmaceuticals announced reaching a 35% enrollment milestone in its ONWARD™ Phase 3 trial, evaluating the efficacy of its drug candidate AD04 for treating Alcohol Use Disorder (AUD) in Europe. The company anticipates hitting 50% enrollment shortly, aided by a decrease in early termination rates and no reported serious adverse events. Amid the COVID-19 pandemic, adjustments have been made for remote participation. The urgent need for effective AUD treatments has intensified due to increased alcohol issues during lockdowns.
FAQ
What is the current stock price of Adial Pharmaceuticals (ADIL)?
What is the market cap of Adial Pharmaceuticals (ADIL)?
